Welcome to our dedicated page for Qualigen Therapeutics news (Ticker: QLGN), a resource for investors and traders seeking the latest updates and insights on Qualigen Therapeutics stock.
Qualigen Therapeutics Inc (QLGN) is an early clinical-stage biopharmaceutical company advancing novel cancer treatments through its investigational G-quadruplex-targeting therapies. This hub provides timely updates on corporate developments, clinical research milestones, and regulatory progress for investors and researchers.
Access press releases covering QN-302 clinical trials, preclinical program updates, financial disclosures, and strategic partnerships. Our curated news collection helps stakeholders track the company’s progress in developing precision oncology treatments while maintaining compliance with financial reporting standards.
Key updates include therapeutic pipeline advancements, peer-reviewed research publications, and material business events. All content is verified through primary sources to ensure accuracy and relevance for investment analysis and scientific evaluation.
Bookmark this page for consolidated access to Qualigen Therapeutics’ latest developments in cancer drug discovery and corporate announcements. Check regularly for authoritative updates on their innovative approach to targeting transcription mechanisms in malignant cells.
Qualigen Therapeutics (NASDAQ: QLGN) announced the official launch of its C10 Cryptocurrency Asset Treasury (DAT) purchases, with buying set to begin next week.
The company said it established USD settlement, bank accounts, and crypto custody but has not purchased any virtual currencies yet. Management framed the recent crypto pullback as a deleveraging event—citing $16 billion in leveraged liquidations and ~$200 billion wiped from market cap—and said Ethena's USDe unpegging contributed ~10–15% of liquidations. CXC10 will use an 80/20 passive/active allocation, expand hedging tools, pursue strategic M&A, and promote C10 private and ETF products to grow assets under management.
Qualigen Therapeutics (NASDAQ: QLGN) announced leadership, board and auditor changes in early October 2025 to support its next growth phase. Effective October 2, 2025, Jerry (Jiawei) Wang was named Co-CEO and Koti Meka named CFO. The Board expanded after a September 29, 2025 private placement, adding Kevin Chen, Chad Chen, and Jay Sheng with committee assignments for audit, nominating & governance, and compensation. Audit firm Withum resigned effective October 1, 2025, and the Audit Committee approved engagement of MGO to audit the fiscal year ending December 31, 2025, subject to client acceptance procedures.
The company reported the board resignations were amicable and not due to disagreements with operations or policies.
Qualigen Therapeutics (NASDAQ: QLGN) has announced the successful closing of a $41 million PIPE financing, primarily led by Faraday Future (NASDAQ: FFAI). The financing includes a $30 million investment from FF, representing approximately 55% ownership, and a $4 million personal investment from FF's Founder YT Jia.
The company is undergoing a strategic transformation into a Web3- and crypto-focused business, planning to rebrand as CXC10. The new business will focus on three main areas: C10 Digital Asset Treasury, DeAI Agent trading platform, and RWA & Ecosystem Tokens. As part of this transformation, Jerry Wang joins as Co-CEO, and FF's CFO Koti Meka assumes the CFO role at QLGN.
Faraday Future (NASDAQ: FFAI) has announced a strategic $41 million PIPE investment in Qualigen Therapeutics (NASDAQ: QLGN), marking a significant shift into crypto and Web3 business. The investment, led by FF and its Founder YT Jia, includes a $30 million investment from FF at $2.246 per share (55% ownership) and a $4 million personal investment from YT Jia (7% ownership).
Following the transaction, FF and YT Jia will control approximately 62% of QLGN's outstanding shares. The deal includes significant management changes, with YT Jia becoming Chief Advisor, Jerry Wang appointed as Co-CEO, and FF gaining board nomination rights. The structure allows FF to maintain its EV focus while expanding into crypto through QLGN.
Qualigen Therapeutics (NASDAQ: QLGN) received two communications from Nasdaq regarding its listing status. The company was notified on July 23, 2025, about non-compliance with the $2.5 million stockholder's equity requirement. In response, QLGN has successfully addressed three key requirements: filing its Q1 2025 10-Q by July 21, regaining compliance through a $4.5 million private placement of Series A-3 Preferred Stock, and submitting a compliance maintenance plan to Nasdaq.
The company plans to file an 8-K including a pro forma balance sheet demonstrating compliance with stockholder's equity requirements, though it cautions there's no guarantee of maintaining Nasdaq listing standards.
Qualigen Therapeutics (NASDAQ:QLGN), a life sciences company focused on cancer treatments, has secured $4.5 million in private placement funding through the sale of Series A-3 Preferred Stock. The company sold 4,500 shares at $1,000 per share to institutional and accredited investors.
The Series A-3 Preferred Stock is convertible into 1,607,143 common shares at an initial conversion price of $2.80 per share. Univest, LLC served as the exclusive placement agent, and the proceeds will be used for working capital purposes. The company has committed to filing a registration statement with the SEC within 45 days for the resale of the underlying common shares.
Qualigen Therapeutics (NASDAQ: QLGN) has announced significant patent developments for its drug QN-302 in the first half of 2025. The company has secured patents titled "Substitued Naphthalene Diimides and Their Use" across 25 countries, including major markets in Europe, India, China, and Russia.
The drug, originally developed by Professor Stephen Neidle's team at University College London and licensed by Qualigen, is targeted at treating Pancreatic and Gastrointestinal Cancer. These patents, which extend into 2040, cover both the product and its manufacturing methods.
Qualigen Therapeutics (NASDAQ: QLGN) has received a deficiency notification from Nasdaq on May 19, 2025, due to its failure to file the Q1 2025 Form 10-Q on time. This notification adds to existing listing compliance issues and will be considered by the Nasdaq Hearings Panel as an additional basis for potential delisting from The Nasdaq Stock Market. The company plans to present its compliance plan at a previously scheduled hearing and is working to complete and file the delayed quarterly report. However, there is no guarantee that Nasdaq will grant an extension or that Qualigen will regain compliance with listing requirements.
Qualigen Therapeutics (NASDAQ: QLGN) has entered a non-binding Memorandum of Understanding (MOU) to acquire Marizyme (OTC: MRZM), following their 2024 co-marketing agreement. The acquisition targets the $10 billion Coronary Artery Bypass Graft (CABG) market through Marizyme's FDA-cleared DuraGraft technology.
DuraGraft addresses a critical need in CABG surgeries, where saphenous vein graft failure rates reach 20-40% within the first year and approximately 50% within 5-10 years. The technology aims to prevent oxidative damage and slow vein graft failure progression, potentially reducing repeat procedures and hospital stays.
The deal, subject to due diligence, final terms, and shareholder approval, is expected to generate revenue by the end of fiscal 2025, with commercialization strategy development planned for the third quarter.
FAQ
What is the current stock price of Qualigen Therapeutics (QLGN)?
What is the market cap of Qualigen Therapeutics (QLGN)?
